Welcome to our dedicated page for Pure Bioscience news (Ticker: PURE), a resource for investors and traders seeking the latest updates and insights on Pure Bioscience stock.
Pure Bioscience Inc (PURE) delivers innovative antimicrobial solutions through its patented silver dihydrogen citrate (SDC) technology, serving healthcare and industrial markets with environmentally conscious bioscience products. This news hub provides investors and industry professionals with timely updates on corporate developments, scientific advancements, and market positioning.
Access verified press releases, financial disclosures, and operational milestones in one centralized location. Key coverage areas include regulatory approvals, product commercialization progress, partnership announcements, and peer-reviewed research findings related to SDC-based solutions. The resource prioritizes factual reporting on technology applications across infection control, food safety, and sustainable sanitation sectors.
Regular updates ensure stakeholders maintain current awareness of PURE's progress in addressing antimicrobial resistance challenges through its non-toxic platform. Content is curated to support informed decision-making without speculative commentary. Bookmark this page for efficient tracking of material developments impacting Pure Bioscience's market presence and technological leadership.
PURE Bioscience will unveil its newest food safety solutions at the 2024 International Association for Food Protection (IAFP) show in Long Beach, California, from July 14th-17th, 2024. The company specializes in non-toxic, chlorine-free food safety products using its patented silver dihydrogen citrate (SDC) molecule. Key products include PURE® Hard Surface, a disinfectant that eliminates bacteria like Listeria and E. coli in 30 seconds, and PURE Control®, an antimicrobial aid for produce and poultry. The event will feature various solutions aimed at improving food safety and sanitation without harmful chemicals.
PURE Bioscience has signed a multi-year international supply and license agreement with AgroVet Alliance. This partnership will see the distribution of PURE's patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial products across the Middle East and North Africa. Jeff Kitchell, VP of Operations at PURE, highlighted the strategic fit between PURE's vision and AVA's established network in the animal health sector. AVA's CEO, Nick Nikooforsat, expressed excitement about offering SDC products to their network, emphasizing the potential business impact for their customers. SDC stands out due to its dual-action mechanism, effectively killing a broad spectrum of microbes and having a long shelf life, unlike traditional silver-based disinfectants.
PURE Bioscience reported its fiscal Q3 2024 financial results, highlighting a net product sales increase to $440,000 from $406,000 YoY, and a reduced net loss of $857,000 from $876,000 YoY. For the nine months ending April 30, 2024, net product sales were up to $1,483,000 from $1,269,000 YoY, with net loss decreasing to $2,594,000 from $2,929,000 YoY. The company is transitioning from a direct sales model to a distributor model, developing new pricing agreements, boosting social media engagement by 167%, and increasing followers by 70%. They continue to participate in trade shows and expand R&D efforts, focusing on food safety and environmental sustainability in industries like dairy and animal health.
PURE Bioscience, Inc. appointed Darin Zehr to its Board of Directors, effective May 1, 2024. Zehr, with extensive experience in the food industry, joins as an independent director and will serve on PURE's Audit and Compensation Committees. He previously worked at Kraft Foods for 22 years and is currently the General Manager of Commercial Food Sanitation Zehr holds a Bachelor of Science degree in Chemistry and brings valuable insights to PURE's Board.
PURE Bioscience, Inc. (OTCQB: PURE) reported its Q2 and six-month results ended January 31, 2023. Net product sales decreased to $396,000 in Q2 from $415,000 in 2022, with a net loss of $1,060,000 compared to $702,000 in the same quarter last year. For the six months, sales totaled $863,000, down from $912,000, with losses rising to $2,053,000 versus $1,498,000 year-over-year. The company appointed Robert Bartlett as the new CEO on March 15, 2023, aiming to enhance revenue and redirect sales strategies.
FAQ
What is the current stock price of Pure Bioscience (PURE)?
What is the market cap of Pure Bioscience (PURE)?
